Retatrutide (designated LY3437943) has become one of the most searched-for research peptides in the UK. This guide explains what it is, what published clinical research has investigated it for, why purity and HPLC verification matter, and what qualified researchers should look for when sourcing it. All information below is for in vitro laboratory research only. Retatrutide is not approved for human or veterinary use and is not for human consumption.
What is Retatrutide?
Retatrutide is a synthetic, investigational-grade peptide engineered as a unimolecular triple agonist that targets three metabolic receptors simultaneously: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GcgR). This triple-receptor profile distinguishes it from dual-agonist compounds and has made it a subject of extensive pre-clinical and clinical investigation.
What has Retatrutide been researched for? Human clinical trials
Compliance note: the studies summarised below describe independent, peer-reviewed clinical research into the retatrutide molecule. They are provided for scientific reference only and are not claims about the product supplied by MMpeptides, which is intended solely for in vitro laboratory research and is not for human or veterinary use.
Since 2023, retatrutide has advanced through several Phase 2 human clinical trials published in leading peer-reviewed journals. The principal areas of investigation have been obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as NAFLD).
Primary sources:
- Obesity — Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023. nejm.org
- Type 2 diabetes — Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial. The Lancet, 2023. pubmed.ncbi.nlm.nih.gov
- Fatty liver / MASLD — Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 2024. nature.com
Obesity (Phase 2, New England Journal of Medicine, 2023)
In a 48-week randomised Phase 2 trial of 338 adults with obesity (Jastreboff et al.), participants receiving the highest dose showed a mean body-weight reduction of approximately 24% compared with placebo, following a clear dose-response relationship. The most commonly reported adverse events were gastrointestinal and were mostly mild to moderate in severity.
Type 2 diabetes (Phase 2, The Lancet, 2023)
In a 24-week randomised Phase 2 trial of 281 adults with type 2 diabetes (Rosenstock et al.), retatrutide was associated with dose-dependent reductions in HbA1c (up to roughly 2 percentage points) and in body weight versus placebo, with the majority of treated participants reaching an HbA1c target of 7%.
Fatty liver / MASLD (Phase 2a, Nature Medicine, 2024)
In a Phase 2a sub-study of 98 participants with MASLD (Sanyal et al.), higher doses of retatrutide were associated with relative reductions in liver-fat content exceeding 80% at 24 weeks versus negligible change in the placebo group, with normalisation of liver fat in a large proportion of participants by 48 weeks.
Taken together, these trials characterise the metabolic effects being studied in the peer-reviewed literature. Retatrutide remains an investigational compound and is not an approved medicine in the UK. Researchers should consult the primary publications for full methodology, endpoints, and safety data.
Why purity and HPLC verification matter
In peptide research, results are only as reliable as the reference material. Impurities, incorrect sequences, or degraded product introduce noise that undermines reproducibility. That is why every batch should be HPLC-verified to ≥99% purity and accompanied by a Certificate of Analysis (COA). When sourcing Retatrutide in the UK, always confirm that the supplier can provide per-batch analytical documentation.
Storage and stability
- Lyophilised (freeze-dried) form: store at −20°C, protected from light and moisture. Stable for up to 24 months from manufacture when stored correctly.
- Reconstituted: store at 4°C and use within 28 days. Do not freeze the reconstituted solution.
Reconstitution
Reconstitute the lyophilised powder with sterile bacteriostatic water. Add the solvent slowly down the vial wall — do not shake. Allow it to stand for 2–3 minutes, then gently swirl until fully dissolved. For a full walkthrough and dosing-volume maths, see our Peptide Reconstitution Guide and the Peptide Calculator.
Available unit sizes
MMpeptides supplies Retatrutide in three research unit sizes so labs can match quantity to experiment scale:
- Retatrutide 5mg — pilot experiments and receptor-binding assays
- Retatrutide 10mg — mid-scale dose–response work
- Retatrutide 20mg — larger in vitro studies and multi-point concentration curves
Buying Retatrutide in the UK
MMpeptides ships from a UK warehouse with same-day dispatch on orders placed before 4pm (Monday–Friday) and free UK delivery on orders over £100. Every product is lyophilised and HPLC-verified to ≥99% purity, supplied strictly for laboratory and in vitro research use.
Frequently asked questions
Is Retatrutide legal to buy in the UK?
Retatrutide is supplied strictly as a research chemical for in vitro laboratory use only. It is not authorised as a medicine and is not for human or veterinary use. Buyers are responsible for observing all applicable regulations in their jurisdiction.
What has Retatrutide been studied for?
Published Phase 2 clinical trials have investigated the retatrutide molecule in the context of obesity, type 2 diabetes, and fatty liver disease (MASLD). These are independent academic studies of the compound, not statements about the research product supplied here.
What purity is MMpeptides Retatrutide?
Every batch is HPLC-verified to ≥99% purity and supplied as a lyophilised solid with a Certificate of Analysis available on request.
How should Retatrutide be stored?
Store the lyophilised vial at −20°C away from light and moisture. Once reconstituted with bacteriostatic water, store at 4°C and use within 28 days.
What is used to reconstitute Retatrutide?
Sterile bacteriostatic water is the standard solvent. Add it slowly to the vial wall and swirl gently rather than shaking.
References
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023. nejm.org
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial. The Lancet, 2023. pubmed.ncbi.nlm.nih.gov
- Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 2024. nature.com
This article is provided for educational and research purposes only. It summarises independent published clinical research into the retatrutide molecule and does not constitute medical advice or a claim about the product supplied. MMpeptides products are supplied for in vitro laboratory research and are not intended for human consumption.